论文部分内容阅读
在白血病中,慢性淋巴细胞白血病(CLL)临床过程和生存期差异极大,有的在确诊后生存期仅数月,有的可生存在20年以上,而死于与CLL无关的疾病,故决定什么时候开始化疗,就成为CLL处理的一个重要问题,曾提出过用各种临床和实验室的参数作为预测CLL病人预后的指征,能为大多数人接受的是Rai′s和国际专题研究组(IW)两个分期系统。病人和方法:复习1960-1982年间所治全部病人资料,诊断根据持续淋巴细胞增加在10×10~9/L以上。1980年以后,常规进行细胞标记测定,仅有单克隆淋巴细胞增生的病人才诊为CLL,其他淋巴细胞增生性疾病的病人不列入研究范围内。
In leukemia, chronic lymphocytic leukemia (CLL) clinical process and the survival of very different, and some confirmed after the survival of only a few months, and some can survive more than 20 years, and died of a disease unrelated to CLL, so Determining when to start chemotherapy is an important issue for CLL management and various clinical and laboratory parameters have been proposed as indications for predicting the prognosis of CLL patients, and most of them can accept Rai’s and international topics Study Group (IW) Two staging systems. PATIENTS AND METHODS: The data of all patients treated between 1960 and 1982 were reviewed and the diagnosis was based on a sustained increase in lymphocytes above 10 × 10 9 / L. After 1980, the routine determination of cell markers, only patients with monoclonal lymphocyte proliferation was diagnosed as CLL, other patients with lymphoproliferative disorders are not included in the study.